Sanofi, pCPA Sign Letter of Intent for Dupixent Across Four Indications
Sanofi and Canada's pCPA signed a Letter of Intent this week covering Dupixent (dupilumab) across four dermatology and respiratory indications. Specific conditions, pricing, and timeline were not dis…